bpc-157 clinical trial human study – No Proof Required! | Office for Science and Society The Real BPC-157 Story: 544

Most patients receive weekly or bi-weekly injections, with regular progress assessments.

In a comprehensive 2018 review published in Current Neuropharmacology , Sikiric and colleagues examined the brain-gut axis interactions of BPC-157 and noted that doses ranging from as low as 10 ng/kg to 10 g/kg produced observable effects in various experimental models (PMID: 28707506)

Enhancing the resistance of BAPPs to proteases while preserving their biological activity remains a challenge due to their relatively short half-lives

In other words, the submission is implicitly conceding FDAs main point: for peptides, the central problem is not only whether a molecule may have biological activity, but whether it can be reproducibly characterized, sourced, tested, and compounded under controlled conditions

To advance science, we must provide these tools to scientists, but their use outside of these controlled environments is inappropriate and, in the case of athletes, a violation of the rules